{
    "clinical_study": {
        "@rank": "92551", 
        "acronym": "MYELAXAT", 
        "arm_group": {
            "arm_group_label": "Apixaban", 
            "arm_group_type": "Experimental", 
            "description": "oral direct anti-Xa anticoagulant"
        }, 
        "brief_summary": {
            "textblock": "To evaluate:\n\n        -  the incidence of venous thromboembolic event (VTE)\n\n        -  the incidence of hemorrhagic complications, In a population of patients with myeloma\n           who are treated with IMiDs and require thromboprophylaxis for 6 months, using an oral\n           anti-Xa anticoagulant, Apixaban, in a preventive scheme, 2.5 mg x2/day"
        }, 
        "brief_title": "Evaluation of the Use of Apixaban in Prevnetion of Thromboembolic Disease in Patients With Myeloma Trated With iMiDs", 
        "completion_date": {
            "#text": "July 2017", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Myeloma", 
            "Venous Thromboembolism"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Multiple Myeloma", 
                "Neoplasms, Plasma Cell", 
                "Thromboembolism", 
                "Venous Thromboembolism", 
                "Venous Thrombosis"
            ]
        }, 
        "detailed_description": {
            "textblock": "MYELAXAT trial is multicentre, open trial which aims to evaluate the incidence of venous\n      thromboembolic event (VTE) and the incidence of hemorrhagic complications. All patients with\n      Myeloma treated with iMiDs and require thromboprophylaxis for 6 months, using an oral\n      anti-Xa anticoagulant, Apixaban, in a preventive scheme, 2.5 mg x2/day"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients (men/women) aged more than 18 years\n\n          -  All consecutive patients, with myeloma, in first-line treatment or in relapse, who\n             are treated - With IMiDs (MPT, Melphalan -Prednisone -Thalidomide ; Lenalidomide -\n             Dexamethasone).\n\n        AND\n\n        - who require prevention of venous thromboembolic events with Aspirin or Low molecular\n        Weight Heparin (LMWH) for a minimum duration of 6 months At least, 2/3 of patients will be\n        treated with Lenalidomide-Dexamethasone.\n\n          -  Written informed consent\n\n          -  Patients affiliated to the French social security system or equivalent\n\n        Exclusion Criteria:\n\n          -  Patient who needs curative anticoagulant treatment (heparin, LMWH, vitamin K\n             antagonists, Dabigatran, Rivaroxaban, Apixaban) for an associated disorder\n             (mechanical valve, atrial fibrillation or venous thromboembolic disease in the\n             previous 6 months).\n\n          -  Patient who needs preventive treatment with an anticoagulant in a post-operative\n             context\n\n          -  Patient who needs anti-platelet treatment (Aspirin, Clopidogrel, Prasugrel,\n             Ticagrelor or dual anti-platelet therapy )\n\n          -  Patient with active bleeding or at a high risk of bleeding (ulcer disease,\n             intracranial bleeding in the previous 6 months, uncontrolled hypertension)\n\n          -  Patient having undergone a surgical intervention within the past 30 days likely to\n             expose them to an haemorrhagic risk\n\n          -  Active hepatic disease (hepatitis, cirrhosis)\n\n          -  Severe renal insufficiency (creatinine clearance using the Cockcroft equation < 30\n             ml/mn)\n\n          -  Known allergic reaction to Apixaban\n\n          -  Contraindication to the use of an anticoagulant treatment\n\n          -  Prohibited concomitant treatment\n\n               -  inhibitors of CYP3A4 and P-gp  : azole antimycotic agents (ketoconazole,\n                  itraconazole, voriconazole, posaconazole), inhibitors of HIV protease\n                  (ritonavir, indinavir, nelfinavir, atazanavir, saquinavir), specific macrolide\n                  antibiotics (clarithromycine, telithromycine)\n\n               -  other antithrombotic treatment : salicylate derivates (aspirin, products\n                  containing aspirin), antiplatelet therapy, heparin (unfractionated heparin, low\n                  molecular weight heparin, danaparoide sodique, fondaparinux), hirudines, oral\n                  anticoagulants (vitamin K antagonists, rivaroxaban, dabigatran)\n\n          -  Patient with AST or ALT  rate > 3 times upper limit of normal\n\n          -  Patient with Bilirubin rate  > 1.5 times upper limit of normal\n\n          -  Patient with Platelets rate < 75 G/l\n\n          -  Patient with Creatinine Clearance (Cockcroft) < 30 ml/mn\n\n          -  Incidental finding of a proximal Deep Venous Thrombosis on the screening ultrasound\n\n          -  Patients refusing or unable to give a written consent of information\n\n          -  Patient unable to comply with the protocol requirement, in the investigator's opinion\n\n          -  Life expectancy less than  6 months\n\n          -  Incarcerated patients\n\n          -  Pregnancy or possibility of pregnancy within 6 months\n\n          -  Females of childbearing potential without reliable contraception\n\n          -  Ecog > 2"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "105", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 14, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02066454", 
            "org_study_id": "DCIC 1320", 
            "secondary_id": "2013-003190-99"
        }, 
        "intervention": {
            "arm_group_label": "Apixaban", 
            "description": "2.5mg x 2 per day during 6 months", 
            "intervention_name": "Apixaban", 
            "intervention_type": "Drug", 
            "other_name": "oral direct anti-Xa anticoagulant"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Anticoagulants", 
                "Heparin, Low-Molecular-Weight", 
                "Dalteparin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "myeloma", 
            "antiXa anticoagulant", 
            "venous thromboembolic disease", 
            "iMiDs"
        ], 
        "lastchanged_date": "March 14, 2014", 
        "location": [
            {
                "contact": {
                    "last_name": "Fr\u00e9d\u00e9rique ORSINI, MD", 
                    "phone": "04 50 63 66 08"
                }, 
                "facility": {
                    "address": {
                        "city": "Annecy", 
                        "country": "France", 
                        "zip": "74374"
                    }, 
                    "name": "CHRA"
                }, 
                "investigator": [
                    {
                        "last_name": "Fr\u00e9d\u00e9rique ORSINI, MD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Pascale CONY-MAKHOUL, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Anne PARRY, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Bernadette CORRONT, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "DAGUINDAU Nicolas, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "abanos@ch-cotebasque.fr", 
                    "last_name": "Anne BANOS, MD", 
                    "phone": "05 59 44 38 32"
                }, 
                "facility": {
                    "address": {
                        "city": "Bayonne", 
                        "country": "France", 
                        "zip": "64100"
                    }, 
                    "name": "Ch La Cote Basque"
                }, 
                "investigator": [
                    {
                        "last_name": "Anne BANOS, MD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Carla ARAUJO, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "thderevel@gmail.com", 
                    "last_name": "Thierry DE REVEL, MD", 
                    "phone": "01 41 46 63 01"
                }, 
                "facility": {
                    "address": {
                        "city": "Clamart", 
                        "country": "France", 
                        "zip": "92141"
                    }, 
                    "name": "Hia Percy"
                }, 
                "investigator": {
                    "last_name": "Thierry DE REVEL, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "karim.belhadj@hmn.aphp.fr", 
                    "last_name": "Karim BELHADJ-MERZOUG, MD", 
                    "phone": "01 49 81 49 63"
                }, 
                "facility": {
                    "address": {
                        "city": "Creteil", 
                        "country": "France", 
                        "zip": "94010"
                    }, 
                    "name": "Chu Hopital Henri Mondor"
                }, 
                "investigator": {
                    "last_name": "Karim BELHADJ-MERZOUG, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "marc.wetterwald@ch-dunkerque.fr", 
                    "last_name": "Marc WETTERWALD, MD", 
                    "phone": "03 28 28 56 33"
                }, 
                "facility": {
                    "address": {
                        "city": "Dunkerque", 
                        "country": "France", 
                        "zip": "59385"
                    }, 
                    "name": "Centre Hospitalier"
                }, 
                "investigator": {
                    "last_name": "Marc WETTERWALD, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "bpegourie@chu-grenoble.fr", 
                    "last_name": "Brigitte PEGOURIE, MD", 
                    "phone": "04 76 76 55 90"
                }, 
                "facility": {
                    "address": {
                        "city": "Grenoble", 
                        "country": "France", 
                        "zip": "38043"
                    }, 
                    "name": "Chu Grenoble"
                }, 
                "investigator": [
                    {
                        "last_name": "Brigitte PEGOURIE, MD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "R\u00e9my GRESSIN, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Lysiane MOLINA, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Audrey SIMON, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "St\u00e9phane COURBY, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Claude-Eric BULABOIS, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Anne THIEBAUT, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Jean-Yves CAHN, PHD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "mourad.tiab@chd-vendee.fr", 
                    "last_name": "Mourad TIAB, MD", 
                    "phone": "02 51 44 61 73"
                }, 
                "facility": {
                    "address": {
                        "city": "La Roche Sur Yon", 
                        "country": "France", 
                        "zip": "85925"
                    }, 
                    "name": "Chd Vendee"
                }, 
                "investigator": {
                    "last_name": "Mourad TIAB, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eric VOOG, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Le Mans", 
                        "country": "France", 
                        "zip": "72000"
                    }, 
                    "name": "Clinique Victor Hugo"
                }, 
                "investigator": {
                    "last_name": "Eric VOOG, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "thierry.facon@chru-lille.fr", 
                    "last_name": "Thierry FACON, MD", 
                    "phone": "03 20 44 57 12"
                }, 
                "facility": {
                    "address": {
                        "city": "Lille", 
                        "country": "France", 
                        "zip": "59037"
                    }, 
                    "name": "Chru Hopital Huriez"
                }, 
                "investigator": [
                    {
                        "last_name": "Thierry FACON, MD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Xavier LELEU, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "cliquennois.manuel@ghicl.net", 
                    "last_name": "Manuel CLIQUENNOIS, MD", 
                    "phone": "03 20 87 45 32"
                }, 
                "facility": {
                    "address": {
                        "city": "Lille", 
                        "country": "France", 
                        "zip": "59020"
                    }, 
                    "name": "Hopital St Vincent - Ghicl"
                }, 
                "investigator": {
                    "last_name": "Manuel CLIQUENNOIS, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "philippe.rey@lyon.unicancer.fr", 
                    "last_name": "Philippe REY, MD", 
                    "phone": "04 78 78 67 95"
                }, 
                "facility": {
                    "address": {
                        "city": "Lyon", 
                        "country": "France", 
                        "zip": "69373"
                    }, 
                    "name": "Centre Leon Berard"
                }, 
                "investigator": [
                    {
                        "last_name": "Philippe REY, MD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Catherine SEBAN, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Pierre BIRON, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "charles.zarnitsky@ch-havre.fr", 
                    "last_name": "Charles ZARNITSKY, MD", 
                    "phone": "02 32 73 33 78"
                }, 
                "facility": {
                    "address": {
                        "city": "Montivilliers", 
                        "country": "France", 
                        "zip": "76290"
                    }, 
                    "name": "Groupe Hospitalier Du Havre"
                }, 
                "investigator": {
                    "last_name": "Charles ZARNITSKY, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "fuzibet.jg@chu-nice.fr", 
                    "last_name": "Jean-Gabriel FUZIBET, MD", 
                    "phone": "04 92 03 58 23"
                }, 
                "facility": {
                    "address": {
                        "city": "Nice", 
                        "country": "France", 
                        "zip": "06202"
                    }, 
                    "name": "Hopital de L'Archet"
                }, 
                "investigator": {
                    "last_name": "Jean-Gabriel FUZIBET, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "damienroosweil@voila.fr", 
                    "last_name": "Damien ROOS-WEIL, MD", 
                    "phone": "01 42 16 28 34"
                }, 
                "facility": {
                    "address": {
                        "city": "Paris", 
                        "country": "France", 
                        "zip": "75651"
                    }, 
                    "name": "Hopital Pitie Salpetriere"
                }, 
                "investigator": [
                    {
                        "last_name": "Damien ROOS-WEIL, MD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "V\u00e9ronique MOREL-MALEK, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "rodon.philippe@wanadoo.fr", 
                    "last_name": "Philippe RODON, MD", 
                    "phone": "05 53 45 29 78"
                }, 
                "facility": {
                    "address": {
                        "city": "Perigueux", 
                        "country": "France", 
                        "zip": "24000"
                    }, 
                    "name": "Ch de Perigueux"
                }, 
                "investigator": {
                    "last_name": "Philippe RODON, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "gerald.marit@chu-bordeaux.fr", 
                    "last_name": "G\u00e9rald MARIT, MD", 
                    "phone": "05 57 65 65 11"
                }, 
                "facility": {
                    "address": {
                        "city": "Pessac", 
                        "country": "France", 
                        "zip": "33604"
                    }, 
                    "name": "Chu Bordeaux"
                }, 
                "investigator": [
                    {
                        "last_name": "G\u00e9rald MARIT, MD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Axelle LASCAUX, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Sophie DIMICOLI-SALAZAR, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "lionel.karlin@chu-lyon.fr", 
                    "last_name": "Lionel KARLIN, MD", 
                    "phone": "04 78 86 43 09"
                }, 
                "facility": {
                    "address": {
                        "city": "Pierre Benite", 
                        "country": "France", 
                        "zip": "69310"
                    }, 
                    "name": "Ch Lyon Sud"
                }, 
                "investigator": {
                    "last_name": "Lionel KARLIN, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "i.azais@chu-poitiers.fr", 
                    "last_name": "Isabelle AZAIS, MD", 
                    "phone": "05 49 44 44 65"
                }, 
                "facility": {
                    "address": {
                        "city": "Poitiers", 
                        "country": "France", 
                        "zip": "86021"
                    }, 
                    "name": "Chu Poitiers"
                }, 
                "investigator": {
                    "last_name": "Isabelle AZAIS, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Lotfi BENBOUKER, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Tours", 
                        "country": "France", 
                        "zip": "37000"
                    }, 
                    "name": "Chru de Tours"
                }, 
                "investigator": {
                    "last_name": "Lotfi BENBOUKER, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "1", 
        "official_title": "Evaluation of the Use of an Oral Direct Anti-Xa Anticoagulant, Apixaban, in Prevention of Venous Thromboembolic Disease in Patients Treated With IMiDs During Myeloma : a Pilot Study", 
        "overall_contact": {
            "email": "bpegourie@chu-grenoble.fr", 
            "last_name": "Brigitte PEGOURIE, MD", 
            "phone": "04 76 76 55 90"
        }, 
        "overall_contact_backup": {
            "email": "gpernod@chu-grenoble.fr", 
            "last_name": "Gilles PERNOD, PHD", 
            "phone": "04 76 76 34 60"
        }, 
        "overall_official": [
            {
                "affiliation": "Hospital University Grenoble", 
                "last_name": "Brigitte PEGOURIE, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Hospital University  Grenoble", 
                "last_name": "Gilles PERNOD, PHD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
                "France: The Commission nationale de l\u2019informatique et des libert\u00e9s"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "January 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Total VTE (fatal or non fatal pulmonary embolism, symptomatic distal or proximal DVT of lower limbs, and asymptomatic proximal DVT detected by bilateral compression ultrasound) and VTE-related death.\n- Major and clinically relevant non major bleeding, defined according to International Society of Thrombosis and haemostasis", 
            "measure": "Total VTE and VTE-related death.  Major and clinically relevant non major bleeding  - Major and clinically relevant non major bleeding, defined according to International Society of Thrombosis and haemostasis", 
            "safety_issue": "Yes", 
            "time_frame": "7 months"
        }, 
        "reference": [
            {
                "PMID": "23216615", 
                "citation": "Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, Porcari A, Raskob GE, Weitz JI; PLIFY-EXT Investigators. Apixaban for extended treatment of venous thromboembolism. N Engl J Med. 2013 Feb 21;368(8):699-708. doi: 10.1056/NEJMoa1207541. Epub 2012 Dec 8."
            }, 
            {
                "PMID": "12780791", 
                "citation": "Anagnostopoulos A, Weber D, Rankin K, Delasalle K, Alexanian R. Thalidomide and dexamethasone for resistant multiple myeloma. Br J Haematol. 2003 Jun;121(5):768-71."
            }, 
            {
                "PMID": "22571202", 
                "citation": "Attal M, Lauwers-Cances V, Marit G, Caillot D, Moreau P, Facon T, Stoppa AM, Hulin C, Benboubker L, Garderet L, Decaux O, Leyvraz S, Vekemans MC, Voillat L, Michallet M, Pegourie B, Dumontet C, Roussel M, Leleu X, Mathiot C, Payen C, Avet-Loiseau H, Harousseau JL; IFM Investigators. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012 May 10;366(19):1782-91. doi: 10.1056/NEJMoa1114138."
            }, 
            {
                "PMID": "11435324", 
                "citation": "Barlogie B, Desikan R, Eddlemon P, Spencer T, Zeldis J, Munshi N, Badros A, Zangari M, Anaissie E, Epstein J, Shaughnessy J, Ayers D, Spoon D, Tricot G. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood. 2001 Jul 15;98(2):492-4."
            }, 
            {
                "PMID": "16342649", 
                "citation": "Baz R, Li L, Kottke-Marchant K, Srkalovic G, McGowan B, Yiannaki E, Karam MA, Faiman B, Jawde RA, Andresen S, Zeldis J, Hussein MA. The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma. Mayo Clin Proc. 2005 Dec;80(12):1568-74."
            }, 
            {
                "PMID": "15701913", 
                "citation": "Blom JW, Doggen CJ, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA. 2005 Feb 9;293(6):715-22."
            }, 
            {
                "PMID": "21255254", 
                "citation": "Carrier M, Le Gal G, Tay J, Wu C, Lee AY. Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: a systematic review and meta-analysis. J Thromb Haemost. 2011 Apr;9(4):653-63. doi: 10.1111/j.1538-7836.2011.04215.x. Review."
            }, 
            {
                "PMID": "15257934", 
                "citation": "Cavo M, Zamagni E, Tosi P, Cellini C, Cangini D, Tacchetti P, Testoni N, Tonelli M, de Vivo A, Palareti G, Tura S, Baccarani M. First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma. Haematologica. 2004 Jul;89(7):826-31."
            }, 
            {
                "PMID": "19545290", 
                "citation": "Chen C, Reece DE, Siegel D, Niesvizky R, Boccia RV, Stadtmauer EA, Abonour R, Richardson P, Matous J, Kumar S, Bahlis NJ, Alsina M, Vescio R, Coutre SE, Pietronigro D, Knight RD, Zeldis JB, Rajkumar V. Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma. Br J Haematol. 2009 Jul;146(2):164-70. doi: 10.1111/j.1365-2141.2009.07728.x. Epub 2009 May 26."
            }, 
            {
                "PMID": "16439370", 
                "citation": "Cohen AT, Davidson BL, Gallus AS, Lassen MR, Prins MH, Tomkowski W, Turpie AG, Egberts JF, Lensing AW; ARTEMIS Investigators. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. BMJ. 2006 Feb 11;332(7537):325-9. Epub 2006 Jan 26."
            }, 
            {
                "PMID": "23388003", 
                "citation": "Cohen AT, Spiro TE, B\u00fcller HR, Haskell L, Hu D, Hull R, Mebazaa A, Merli G, Schellong S, Spyropoulos AC, Tapson V; MAGELLAN Investigators. Rivaroxaban for thromboprophylaxis in acutely ill medical patients. N Engl J Med. 2013 Feb 7;368(6):513-23. doi: 10.1056/NEJMoa1111096."
            }, 
            {
                "PMID": "21309657", 
                "citation": "Connolly SJ, Eikelboom J, Joyner C, Diener HC, Hart R, Golitsyn S, Flaker G, Avezum A, Hohnloser SH, Diaz R, Talajic M, Zhu J, Pais P, Budaj A, Parkhomenko A, Jansky P, Commerford P, Tan RS, Sim KH, Lewis BS, Van Mieghem W, Lip GY, Kim JH, Lanas-Zanetti F, Gonzalez-Hermosillo A, Dans AL, Munawar M, O'Donnell M, Lawrence J, Lewis G, Afzal R, Yusuf S; AVERROES Steering Committee and Investigators. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011 Mar 3;364(9):806-17. doi: 10.1056/NEJMoa1007432. Epub 2011 Feb 10."
            }, 
            {
                "PMID": "18032762", 
                "citation": "Dimopoulos M, Spencer A, Attal M, Prince HM, Harousseau JL, Dmoszynska A, San Miguel J, Hellmann A, Facon T, Fo\u00e0 R, Corso A, Masliak Z, Olesnyckyj M, Yu Z, Patin J, Zeldis JB, Knight RD; Multiple Myeloma (010) Study Investigators. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med. 2007 Nov 22;357(21):2123-32."
            }, 
            {
                "PMID": "17920916", 
                "citation": "Facon T, Mary JY, Hulin C, Benboubker L, Attal M, Pegourie B, Renaud M, Harousseau JL, Guillerm G, Chaleteix C, Dib M, Voillat L, Maisonneuve H, Troncy J, Dorvaux V, Monconduit M, Martin C, Casassus P, Jaubert J, Jardel H, Doyen C, Kolb B, Anglaret B, Grosbois B, Yakoub-Agha I, Mathiot C, Avet-Loiseau H; Intergroupe Francophone du Myelome. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet. 2007 Oct 6;370(9594):1209-18."
            }, 
            {
                "PMID": "22077144", 
                "citation": "Goldhaber SZ, Leizorovicz A, Kakkar AK, Haas SK, Merli G, Knabb RM, Weitz JI; ADOPT Trial Investigators. Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. N Engl J Med. 2011 Dec 8;365(23):2167-77. doi: 10.1056/NEJMoa1110899. Epub 2011 Nov 13."
            }, 
            {
                "PMID": "10737280", 
                "citation": "Heit JA, Silverstein MD, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ 3rd. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med. 2000 Mar 27;160(6):809-15."
            }, 
            {
                "PMID": "16732369", 
                "citation": "Hussein MA. Thromboembolism risk reduction in multiple myeloma patients treated with immunomodulatory drug combinations. Thromb Haemost. 2006 Jun;95(6):924-30. Review."
            }, 
            {
                "PMID": "18805967", 
                "citation": "Johnson DC, Corthals S, Ramos C, Hoering A, Cocks K, Dickens NJ, Haessler J, Goldschmidt H, Child JA, Bell SE, Jackson G, Baris D, Rajkumar SV, Davies FE, Durie BG, Crowley J, Sonneveld P, Van Ness B, Morgan GJ. Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotyping. Blood. 2008 Sep 19; [Epub ahead of print]"
            }, 
            {
                "PMID": "20299513", 
                "citation": "Kristinsson SY, Pfeiffer RM, Bj\u00f6rkholm M, Goldin LR, Schulman S, Blimark C, Mellqvist UH, Wahlin A, Turesson I, Landgren O. Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based study. Blood. 2010 Jun 17;115(24):4991-8. doi: 10.1182/blood-2009-11-252072. Epub 2010 Mar 18. Erratum in: Blood. 2011 Apr 7;117(14):3938."
            }, 
            {
                "PMID": "20206776", 
                "citation": "Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Hornick P; ADVANCE-2 investigators. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet. 2010 Mar 6;375(9717):807-15. doi: 10.1016/S0140-6736(09)62125-5."
            }, 
            {
                "PMID": "15289368", 
                "citation": "Leizorovicz A, Cohen AT, Turpie AG, Olsson CG, Vaitkus PT, Goldhaber SZ; PREVENT Medical Thromboprophylaxis Study Group. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation. 2004 Aug 17;110(7):874-9. Epub 2004 Aug 2. PubMed PMID: 15289368."
            }, 
            {
                "PMID": "22409262", 
                "citation": "Levine MN, Gu C, Liebman HA, Escalante CP, Solymoss S, Deitchman D, Ramirez L, Julian J. A randomized phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancer. J Thromb Haemost. 2012 May;10(5):807-14. doi: 10.1111/j.1538-7836.2012.04693.x."
            }, 
            {
                "PMID": "20339094", 
                "citation": "Libourel EJ, Sonneveld P, van der Holt B, de Maat MP, Leebeek FW. High incidence of arterial thrombosis in young patients treated for multiple myeloma: results of a prospective cohort study. Blood. 2010 Jul 8;116(1):22-6. doi: 10.1182/blood-2009-12-257519. Epub 2010 Mar 25."
            }, 
            {
                "PMID": "17968019", 
                "citation": "Lyman GH, Khorana AA, Falanga A, Clarke-Pearson D, Flowers C, Jahanzeb M, Kakkar A, Kuderer NM, Levine MN, Liebman H, Mendelson D, Raskob G, Somerfield MR, Thodiyil P, Trent D, Francis CW; American Society of Clinical Oncology. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol. 2007 Dec 1;25(34):5490-505. Epub 2007 Oct 29. Review."
            }, 
            {
                "PMID": "12637329", 
                "citation": "Mileshkin L, Biagi JJ, Mitchell P, Underhill C, Grigg A, Bell R, McKendrick J, Briggs P, Seymour JF, Lillie K, Smith JG, Zeldis JB, Prince HM. Multicenter phase 2 trial of thalidomide in relapsed/refractory multiple myeloma: adverse prognostic impact of advanced age. Blood. 2003 Jul 1;102(1):69-77. Epub 2003 Mar 13."
            }, 
            {
                "PMID": "15470485", 
                "citation": "Minnema MC, Breitkreutz I, Auwerda JJ, van der Holt B, Cremer FW, van Marion AM, Westveer PH, Sonneveld P, Goldschmidt H, Lokhorst HM. Prevention of venous thromboembolism with low molecular-weight heparin in patients with multiple myeloma treated with thalidomide and chemotherapy. Leukemia. 2004 Dec;18(12):2044-6."
            }, 
            {
                "PMID": "12429624", 
                "citation": "Neben K, Moehler T, Benner A, Kraemer A, Egerer G, Ho AD, Goldschmidt H. Dose-dependent effect of thalidomide on overall survival in relapsed multiple myeloma. Clin Cancer Res. 2002 Nov;8(11):3377-82."
            }, 
            {
                "PMID": "11419443", 
                "citation": "Osman K, Comenzo R, Rajkumar SV. Deep venous thrombosis and thalidomide therapy for multiple myeloma. N Engl J Med. 2001 Jun 21;344(25):1951-2."
            }, 
            {
                "PMID": "15297848", 
                "citation": "Palumbo A, Bertola A, Falco P, Rosato R, Cavallo F, Giaccone L, Bringhen S, Musto P, Pregno P, Caravita T, Ciccone G, Boccadoro M. Efficacy of low-dose thalidomide and dexamethasone as first salvage regimen in multiple myeloma. Hematol J. 2004;5(4):318-24."
            }, 
            {
                "PMID": "16530576", 
                "citation": "Palumbo A, Bringhen S, Caravita T, Merla E, Capparella V, Callea V, Cangialosi C, Grasso M, Rossini F, Galli M, Catalano L, Zamagni E, Petrucci MT, De Stefano V, Ceccarelli M, Ambrosini MT, Avonto I, Falco P, Ciccone G, Liberati AM, Musto P, Boccadoro M; Italian Multiple Myeloma Network, GIMEMA. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet. 2006 Mar 11;367(9513):825-31."
            }, 
            {
                "PMID": "16879233", 
                "citation": "Palumbo A, Rus C, Zeldis JB, Rodeghiero F, Boccadoro M; Italian Multiple Myeloma Network, Gimema. Enoxaparin or aspirin for the prevention of recurrent thromboembolism in newly diagnosed myeloma patients treated with melphalan and prednisone plus thalidomide or lenalidomide. J Thromb Haemost. 2006 Aug;4(8):1842-5."
            }, 
            {
                "PMID": "18094721", 
                "citation": "Palumbo A, Rajkumar SV, Dimopoulos MA, Richardson PG, San Miguel J, Barlogie B, Harousseau J, Zonder JA, Cavo M, Zangari M, Attal M, Belch A, Knop S, Joshua D, Sezer O, Ludwig H, Vesole D, Blad\u00e9 J, Kyle R, Westin J, Weber D, Bringhen S, Niesvizky R, Waage A, von Lilienfeld-Toal M, Lonial S, Morgan GJ, Orlowski RZ, Shimizu K, Anderson KC, Boccadoro M, Durie BG, Sonneveld P, Hussein MA; International Myeloma Working Group. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia. 2008 Feb;22(2):414-23. Epub 2007 Dec 20. Review."
            }, 
            {
                "PMID": "18505783", 
                "citation": "Palumbo A, Bringhen S, Liberati AM, Caravita T, Falcone A, Callea V, Montanaro M, Ria R, Capaldi A, Zambello R, Benevolo G, Derudas D, Dore F, Cavallo F, Gay F, Falco P, Ciccone G, Musto P, Cavo M, Boccadoro M. Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial. Blood. 2008 Oct 15;112(8):3107-14. Epub 2008 May 27."
            }, 
            {
                "citation": "Palumbo A, Davies F, Kropff M et al. Consensus guidelines for the optimal management of adverse events in newly diagnosed, transplant-ineligible patients receiving melphalan and prednisone in combination with thalidomide (MPT) for the treatment of multiple myeloma. Ann Hematol 2010 89: 803-811"
            }, 
            {
                "PMID": "12409330", 
                "citation": "Rajkumar SV, Hayman S, Gertz MA, Dispenzieri A, Lacy MQ, Greipp PR, Geyer S, Iturria N, Fonseca R, Lust JA, Kyle RA, Witzig TE. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol. 2002 Nov 1;20(21):4319-23."
            }, 
            {
                "PMID": "12682636", 
                "citation": "Rajkumar SV, Gertz MA, Lacy MQ, Dispenzieri A, Fonseca R, Geyer SM, Iturria N, Kumar S, Lust JA, Kyle RA, Greipp PR, Witzig TE. Thalidomide as initial therapy for early-stage myeloma. Leukemia. 2003 Apr;17(4):775-9."
            }, 
            {
                "PMID": "16118317", 
                "citation": "Rajkumar SV, Hayman SR, Lacy MQ, Dispenzieri A, Geyer SM, Kabat B, Zeldenrust SR, Kumar S, Greipp PR, Fonseca R, Lust JA, Russell SJ, Kyle RA, Witzig TE, Gertz MA. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood. 2005 Dec 15;106(13):4050-3. Epub 2005 Aug 23."
            }, 
            {
                "PMID": "16365178", 
                "citation": "Rajkumar SV, Blood E, Vesole D, Fonseca R, Greipp PR; Eastern Cooperative Oncology Group. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol. 2006 Jan 20;24(3):431-6. Epub 2005 Dec 19."
            }, 
            {
                "PMID": "19853510", 
                "citation": "Rajkumar SV, Jacobus S, Callander NS, Fonseca R, Vesole DH, Williams ME, Abonour R, Siegel DS, Katz M, Greipp PR; Eastern Cooperative Oncology Group. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol. 2010 Jan;11(1):29-37. Epub 2009 Oct 21. Erratum in: Lancet Oncol. 2010 Jan;11(1):14."
            }, 
            {
                "PMID": "10477777", 
                "citation": "Samama MM, Cohen AT, Darmon JY, Desjardins L, Eldor A, Janbon C, Leizorovicz A, Nguyen H, Olsson CG, Turpie AG, Weisslinger N. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med. 1999 Sep 9;341(11):793-800."
            }, 
            {
                "PMID": "19185783", 
                "citation": "Samama CM. [Perioperative venous thromboembolism prophylaxis: short review and recommendations]. Ann Fr Anesth Reanim. 2008 Dec;27 Suppl 3:S2-8. doi: 10.1016/S0750-7658(08)75140-2. Review. French."
            }, 
            {
                "PMID": "12860011", 
                "citation": "Schey SA, Cavenagh J, Johnson R, Child JA, Oakervee H, Jones RW. An UK myeloma forum phase II study of thalidomide; long term follow-up and recommendations for treatment. Leuk Res. 2003 Oct;27(10):909-14."
            }, 
            {
                "PMID": "15613105", 
                "citation": "Sch\u00fctt P, Ebeling P, Buttkereit U, Brandhorst D, Opalka B, Hoiczyk M, Flasshove M, Hense J, Bojko P, Metz K, Moritz T, Seeber S, Nowrousian MR. Thalidomide in combination with vincristine, epirubicin and dexamethasone (VED) for previously untreated patients with multiple myeloma. Eur J Haematol. 2005 Jan;74(1):40-6."
            }, 
            {
                "PMID": "16769594", 
                "citation": "Sidra G, Williams CD, Russell NH, Zaman S, Myers B, Byrne JL. Combination chemotherapy with cyclophosphamide, thalidomide and dexamethasone for patients with refractory, newly diagnosed or relapsed myeloma. Haematologica. 2006 Jun;91(6):862-3."
            }, 
            {
                "PMID": "10564685", 
                "citation": "Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, Munshi N, Anaissie E, Wilson C, Dhodapkar M, Zeddis J, Barlogie B. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 1999 Nov 18;341(21):1565-71. Erratum in: N Engl J Med 2000 Feb 3;342(5):364."
            }, 
            {
                "PMID": "18088252", 
                "citation": "Sj\u00e4lander A, Jansson JH, Bergqvist D, Eriksson H, Carlberg B, Svensson P. Efficacy and safety of anticoagulant prophylaxis to prevent venous thromboembolism in acutely ill medical inpatients: a meta-analysis. J Intern Med. 2008 Jan;263(1):52-60. Review."
            }, 
            {
                "PMID": "15274069", 
                "citation": "Srkalovic G, Cameron MG, Rybicki L, Deitcher SR, Kattke-Marchant K, Hussein MA. Monoclonal gammopathy of undetermined significance and multiple myeloma are associated with an increased incidence of venothromboembolic disease. Cancer. 2004 Aug 1;101(3):558-66."
            }, 
            {
                "citation": "Turpie A G, Lassen MR, ; Eriksson BI, et al. Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Pooled analysis of four studies. Thromb Haemost 2011; 105: 444-53"
            }, 
            {
                "PMID": "12506164", 
                "citation": "Weber D, Rankin K, Gavino M, Delasalle K, Alexanian R. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol. 2003 Jan 1;21(1):16-9."
            }, 
            {
                "PMID": "17107906", 
                "citation": "Wu P, Davies FE, Horton C, Jenner MW, Krishnan B, Alvares CL, Saso R, McCormack R, Dines S, Treleaven JG, Potter MN, Ethell ME, Morgan GJ. The combination of cyclophosphomide, thalidomide and dexamethasone is an effective alternative to cyclophosphamide - vincristine - doxorubicin - methylprednisolone as induction chemotherapy prior to autologous transplantation for multiple myeloma: a case-matched analysis. Leuk Lymphoma. 2006 Nov;47(11):2335-8."
            }, 
            {
                "PMID": "11520815", 
                "citation": "Zangari M, Anaissie E, Barlogie B, Badros A, Desikan R, Gopal AV, Morris C, Toor A, Siegel E, Fink L, Tricot G. Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood. 2001 Sep 1;98(5):1614-5."
            }, 
            {
                "PMID": "12149193", 
                "citation": "Zangari M, Siegel E, Barlogie B, Anaissie E, Saghafifar F, Fassas A, Morris C, Fink L, Tricot G. Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy. Blood. 2002 Aug 15;100(4):1168-71."
            }, 
            {
                "PMID": "15327525", 
                "citation": "Zangari M, Barlogie B, Anaissie E, Saghafifar F, Eddlemon P, Jacobson J, Lee CK, Thertulien R, Talamo G, Thomas T, Van Rhee F, Fassas A, Fink L, Tricot G. Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation. Br J Haematol. 2004 Sep;126(5):715-21."
            }, 
            {
                "PMID": "14679133", 
                "citation": "Zervas K, Dimopoulos MA, Hatzicharissi E, Anagnostopoulos A, Papaioannou M, Mitsouli Ch, Panagiotidis P, Korantzis J, Tzilianos M, Maniatis A; Greek Myeloma Study Group. Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD doxil): a phase II multicenter study. Ann Oncol. 2004 Jan;15(1):134-8."
            }, 
            {
                "PMID": "16790586", 
                "citation": "Zonder JA, Barlogie B, Durie BG, McCoy J, Crowley J, Hussein MA. Thrombotic complications in patients with newly diagnosed multiple myeloma treated with lenalidomide and dexamethasone: benefit of aspirin prophylaxis. Blood. 2006 Jul 1;108(1):403; author reply 404."
            }, 
            {
                "PMID": "14515186", 
                "citation": "Zufferey P, Laporte S, Quenet S, Molliex S, Auboyer C, Decousus H, Mismetti P. Optimal low-molecular-weight heparin regimen in major orthopaedic surgery. A meta-analysis of randomised trials. Thromb Haemost. 2003 Oct;90(4):654-61."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02066454"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "incidence of venous thromboembolic complications, symptomatic and asymptomatic, according to the thrombotic risk stratification of patients (low or high risk)", 
                "measure": "incidence of venous thromboembolic complications", 
                "safety_issue": "Yes", 
                "time_frame": "7 months"
            }, 
            {
                "description": "incidence of venous thromboembolic complications, symptomatic and asymptomatic, according to the time of treatment with iMiDs (diagnosis or relapse)", 
                "measure": "incidence of venous thromboembolic complications", 
                "safety_issue": "Yes", 
                "time_frame": "7 months"
            }, 
            {
                "description": "incidence of major and clinically relevant non major bleeding according to the thrombotic risk strtification of patients (low or high risk)", 
                "measure": "incidence of major and clinically relevant non major bleeding", 
                "safety_issue": "Yes", 
                "time_frame": "7 months"
            }, 
            {
                "description": "incidence of arterial cardiovascular events (myocardial infarction, ischemic stroke, TIA)", 
                "measure": "incidence of arterial cardiovascular events", 
                "safety_issue": "Yes", 
                "time_frame": "7 months"
            }
        ], 
        "source": "University Hospital, Grenoble", 
        "sponsors": {
            "collaborator": {
                "agency": "Celgene Corporation", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "University Hospital, Grenoble", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}